Please Note: CBD Life USA or any of its affiliate companies are not responsible in any way if you fail a drug test. We politely tell any existing or prospective customers to refrain from consuming any hemp derived products if there is even the slightest chance they will have to take a drug tests.
Again, there are a lot of lifestyle factors to take into account when determining where you might stand.
Dosage amount, Frequency of use, just to name a few.
HOWEVER USING A ISOLATE BASED PURE CBD WILL NOT SHOW UP ON A DRUG TEST. NO MATTER WHAT THE DOSEAGE.
In Regards To, Drug Testing; We are ONLY talking about CBD Products that contain small trace amounts of THC ONLY. For the purpose of this topic we are talking about THC in Full Spectrum CBD Products
FALSE POSITIVE - When drug testing is mandated, employers must follow the SAMHSA (Substance Abuse and Mental Health Services Administration) guidelines because it puts them on solid legal ground. Typically, there is an overlap between testing guidelines and accepted cutoff levels for drugs and drug metabolites in confirmatory testing and screening.
THC is widely recognized as being responsible for marijuana's psychoactivity and euphoria, a routine urine drug screen for marijuana use consists of an immunoassay with antibodies that are made to detect it, and its main metabolite, 11-nor-delta9-caboxy-THC (THC-COOH). SAMHSA has set the cutoff level for a positive urine screen in the immunoassay at 50 ng/mL. When the immunoassay screen is positive at the > 50 ng/mL level, a confirmatory GC/MS (Gas Chromatography/Mass Spectrometry) test is performed to verify the positive urine screen. The confirmatory GC/MS has a cutoff level of 15 ng/mL and is specific only to the 11-nor-THCCOOH metabolite. Fortunately, the urine drug screen for THC-COOH is known to have very little cross-reactivity to other cannabinoids that are not psychoactive, such as CBD (cannabidiol), CBG (cannabigerol), CBN (cannabinol), and others.
This is good news for “normal” consumers of CBD/hemp oil and CBD Alternative Health Products That said, individuals using unusually large doses of a cannabinoid-rich hemp oil product (above 1000-2000 mg of hemp oil daily) could theoretically test positive during the initial urinary screen IF the products carry less than .3% THC in them. Although very rare, the urine screen in these cases would likely represent a “false positive” due to other non-THC metabolites or compounds, which may cross-react with the immunoassay. When this is the case, the confirmatory GC/MS test would be negative, since CBD and other cannabinoids will not be detected by the more accurate (and specific) GC/MS screen.
All products on CBD Life USA or any of its affiliate companies carry NO THC and are Isolate based products
For example, hemp contains anywhere from 1/10th to 1/300th of THC found in marijuana. An individual consuming 1000-2000 mg per day of hemp oil would thus consume approximately 3-6 mg of THC. This exceedingly high dose may result in detection of positive urine screen in up to 11% to 23% of assays.
On the other hand, there is some data demonstrating that at daily doses of 0.5mg of THC from 3-5 servings of most commercial CBD-rich hemp oil products, the positive urine screen rate is < 0.2%. Again, most servings of typical high-quality, high-purity CBD-based hemp oil products contain well below 0.1mg of THC and therefore have over 400-600 times less THC than marijuana products.
What does all this mean? Put simply, a consumer who uses a high-quality, scientifically vetted hemp-based product at the standard serving size is highly unlikely to test positive for THC and/or THC-COOH. However, it’s important to be cognizant that extremely high doses may result in a positive urine screen (that would be subsequently shown to be false via GC/MS).
If you have any concern about testing positive for THC when using CBD-containing hemp oil, please seek advice from your health care professional.
Gustafson RA, Kim I, Stout PR, Klette KL, George MP, Moolchan ET, Levine B, Huestis MA. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. J Anal Toxicol. 2004 Apr; 28(3):160-7
Gustafson RA, Levine B, Stout PR, Klette KL, George MP, Moolchan ET, Huestis MA. Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. Clin Chem. 2003 Jul; 49(7):1114-24.
Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA. Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol. 1995 Sep; 19(5):285-91.
Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol. 1996 Oct;20(6):441-52.
Wall ME, Perez-Reyes M. J Clin Pharmacol. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. 1981 Aug-Sep; 21(8-9 Suppl):178S-189S.